Northern Trust Corp Sells 1,550 Shares of Vericel Corporation $VCEL

Northern Trust Corp reduced its position in Vericel Corporation (NASDAQ:VCEL) by 0.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 557,892 shares of the biotechnology company’s stock after selling 1,550 shares during the quarter. Northern Trust Corp owned 1.11% of Vericel worth $24,893,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Captrust Financial Advisors grew its stake in Vericel by 3.4% in the fourth quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company’s stock valued at $336,000 after purchasing an additional 199 shares during the last quarter. Portside Wealth Group LLC grew its stake in Vericel by 9.9% in the first quarter. Portside Wealth Group LLC now owns 6,546 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 591 shares during the last quarter. US Bancorp DE grew its stake in Vericel by 29.9% in the first quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 706 shares during the last quarter. GAMMA Investing LLC grew its stake in Vericel by 34.8% in the first quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 748 shares during the last quarter. Finally, Legato Capital Management LLC grew its stake in Vericel by 16.7% in the first quarter. Legato Capital Management LLC now owns 6,675 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 955 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on VCEL shares. Stephens reiterated an “overweight” rating and issued a $67.00 target price on shares of Vericel in a research note on Monday, June 16th. Canaccord Genuity Group cut their target price on Vericel from $61.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 1st. Finally, Wall Street Zen downgraded Vericel from a “hold” rating to a “sell” rating in a report on Monday, May 12th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $60.40.

Vericel Price Performance

NASDAQ VCEL opened at $36.36 on Monday. The company has a market cap of $1.83 billion, a PE ratio of 303.03 and a beta of 1.33. The stock’s 50 day simple moving average is $38.39 and its 200-day simple moving average is $42.26. Vericel Corporation has a 1-year low of $33.09 and a 1-year high of $63.00.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. The business had revenue of $63.24 million for the quarter, compared to the consensus estimate of $64.61 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The business’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) earnings per share. On average, equities research analysts anticipate that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.